{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_0', '207626', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'with COPD. The PRAC review confirmed', 'that COPD participants treated with ICS are', 'at increased risk of pneumonia; however,', \"the Committee's view was that the benefits\", 'of ICS continue to outweigh their risks. The', 'PRAC also looked whether there were any', 'differences in the risk of pneumonia', 'between these produces, and did not find', 'conclusive evidence of such difference.', 'Decreased bone mineral density and', '- Participants will be informed about the', 'associated fractures', 'Reduction in bone density, and the', 'risk in the informed consent.', 'subsequent risk of fractures, is a known', '- Investigators are informed of the risk in', 'potential risk with corticosteroids. There', 'the IB.', 'may be a modest increase in risk of fracture', '- Instream review of blinded AE/SAE', 'among participants with COPD treated with', 'reports.', 'ICS, but the results are not consistent across', 'individual studies [Christensson, 2008;', 'Lehouck, 2011; Weldon, 2009].', 'In study CTT116853, the incidence of', 'events in the decreased bone mineral density', 'and associated fracture AESI group was', \"low, with an incidence of 0.4' % and 0.7%\", 'in the FF/UMEC/VI and BUD/FOR', 'treatment groups, respectively in the ITT', 'Population up to 24 weeks and 0.5 % in', 'both treatment groups in the EXT', 'Population up to 52 weeks. The majority of', '26']['2017N323364_01', 'CONFIDENTIAL', '2019N398531 (', '207626', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'the fractures in both treatment groups were', 'traumatic in nature.', 'Adrenal suppression', 'Oral corticosteroids are known to have an', '- Investigators are informed of the risk in', 'effect on the hypothalamic-pituitary-adrenal', 'the IB.', '(HPA) axis leading to reduction in cortisol', '- Instream review of blinded AE/SAE', 'production. Due to the low dose and low', 'reports.', 'systemic exposure with ICS, this potential', 'effect is not clear, nor is the possible impact', 'of any change in cortisol.', 'The effect of FF/UMEC/VI on cortisol', 'levels has not been studied. In study', 'CTT116853, no events were reported in the', 'adrenal suppression AESI group for', 'FF/UMEC/VI and BUD/FOR.', 'With respect to the FF/VI clinical', 'development programme, a formal HPA', 'study, using 24-hour serum cortisol', 'measurements, was performed. In addition,', 'multiple studies with COPD (and asthma)', 'participants monitored urinary cortisol.', 'These studies did not show a clinically', 'relevant effect of FF/VI 100/25 on the HPA', 'axis.', 'Participants that have received oral', 'corticosteroids, particularly those who have', 'received significant amounts for long', 'periods of time, will be more susceptible to', '27']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_0', '207626', 'Potential Risk of Clinical Significance', 'Summary of Data/Rationale for Risk', 'Mitigation Strategy', 'this risk of adrenal suppression.', 'The proposed dose (100 mcg) of inhaled FF', 'in this study is unlikely to lead to clinically', 'significant changes in the treatment period', 'since systemic exposure is low.', 'Corticosteroid Associated Eye Disorders', 'Systemic ocular effects (e.g. cataract and', '- Participants will be informed about the', 'glaucoma) may occur with any inhaled', 'risk in the informed consent.', 'corticosteroid, particularly at high doses', '- Investigators are informed of the risk in', 'prescribed for long periods. However, these', 'the IB.', 'effects are much less likely to occur with', '- Appropriate exclusion criteria as specified', 'inhaled corticosteroids compared with oral', 'in Section 6.2 of the protocol.', 'corticosteroids.', '- Instream review of blinded AE/SAE', 'In study CTT116853, the incidence of', 'reports', 'events in the ocular effects AESI group was', '- If a risk is suspected, participants should', 'low, with an incidence of 0.1 % and 0.4 %', 'receive appropriate treatment', 'in the FF/UMEC/VI and BUD/FOR', 'treatment groups, respectively, in the ITT', 'Population up to 24 weeks. There were no', 'events reported in the ocular effects AESI in', 'the EXT Population up to 52 weeks.', 'During studies with FF and FF/VI in asthma', 'participants, and with FF/VI and UMEC/VI', 'in COPD participants, no associated effect', 'on ocular disorders was observed. In', 'addition, no effects on lens opacification', 'were observed on formal ophthalmic', '28']\n\n###\n\n", "completion": "END"}